Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding

6 de septiembre de 2018 actualizado por: Eisai Inc.

A Multicenter Phase 0 Study In Healthy Subjects and Subjects With Either Hepatic Or Renal Impairment To Obtain Plasma For Assessment In Vitro Lenvatinib Protein Binding

E7080-A001-010 is a multicenter, parallel-group study in participants with mild, moderate, or severe hepatic or renal impairment and age-, gender-, and smoking status-matched healthy participants. The primary objective of the study is to obtain plasma from participants for use in in vitro protein binding studies.

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Descripción detallada

E7080-A001-010 is a multicenter, parallel-group study in participants with mild, moderate, or severe hepatic or renal impairment and age-, gender-, and smoking status-matched healthy participants. Approximately 6 participants with each degree (mild, moderate, or severe) of hepatic or renal impairment will be enrolled. Two cohorts of 8 healthy participants will be enrolled. One cohort of healthy participants will be matched to the hepatic-impaired participants, whereas the other will be matched to the renal-impaired participants.

The study has 2 phases. The Pre-study Phase consists of a Screening Period and a Baseline Period. The Study Phase consists of a 2-day Study Period. No lenvatinib will be administered in this study.

The end of the study will be the date of the last study visit for the last participant in the study.

The following estimates are provided:

  • From first participant in to last participant out, the study is expected to take approximately one year to complete.
  • The maximum estimated duration of the study for each participant is anticipated to be approximately 5 weeks.

Tipo de estudio

Intervencionista

Inscripción (Actual)

54

Fase

  • Fase temprana 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Florida
      • Orlando, Florida, Estados Unidos
        • Orlando Clinical Research Center, Inc.
    • Minnesota
      • Minneapolis, Minnesota, Estados Unidos
        • DaVita Clinical Research
    • Tennessee
      • Knoxville, Tennessee, Estados Unidos
        • New Orleans Center for Clinical Research

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 79 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

Key Inclusion Criteria:

  • Male or Female
  • Age, at the time of Informed Consent:

    i. Hepatic Impairment Participants (Including Matched Healthy Participants): 18 to 70 years old, inclusive ii. Renal Impairment Participants (Including Matched Healthy Participants): 18 to 79 years old, inclusive

  • Non-smokers and smokers who smoke no more than 10 cigarettes per day
  • Besides diabetes and, as appropriate, renal or hepatic impairment, participants must have no history of acute or chronic clinically relevant disease or condition, as determined by the investigator.
  • For participants with hepatic impairment:

    • Liver cirrhosis that has been stable;
    • Platelet count >30,000 cells/millimeter cubed (mm^3);
    • Total score on the Child-Pugh classification system between 5 and 6 (Group 1, mild), 7 and 9 (Group 2, moderate), and 10 and 15 (Group 3, severe)
  • For healthy participants:

    • Creatinine clearance ≥ 81 milliliter per minute (mL/min)

  • For participants with renal impairment:

    • Must have a diagnosis of renal impairment that has been stable
    • Must have renal impairment in the following categories based on creatinine clearance values: mild (creatinine clearance, 50 to 80 mL/min), moderate (creatinine clearance, 30 to 49 mL/min), or severe (creatinine clearance, 15 to 29 mL/min) renal impairment

Exclusion Criteria:

Key Exclusion Criteria:

  • Use of any new medication
  • Human immunodeficiency virus (HIV) positive
  • Presence of acute active liver disease or acute liver injury
  • History of significant cardiovascular impairment
  • Positive drug or alcohol test
  • Weight loss or gain of >10% prior to Day 1
  • Receipt of blood or blood products or donation of blood or blood products

For participants with hepatic impairment:

  • History of hepatic transplant, systemic lupus erythematosus, or hepatic coma
  • Received treatment with interferon or pegylated interferon
  • Participants who have encephalopathy >Grade 2, sepsis, or gastrointestinal bleeding; esophageal varices >Grade 2, acute hepatic failure of any etiology, history of surgical portosystemic shunt, renal impairment (creatinine clearance <50 mL/min according to the Cockcroft-Gault formula), and rapidly deteriorating hepatic function
  • Systolic blood pressure (SBP) ≥ 160 millimeters of mercury (mmHg) and/or diastolic blood pressure (DBP) ≥ 100 mmHg

For healthy participants:

• Hemoglobin level less than 12.0 grams per deciliter (g/dL)

For participants with renal impairment:

  • A history of renal transplant
  • SBP ≥ 160 mmHg and/or DBP ≥ 100 mmHg for participants with mild renal impairment; SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg for participants with moderate and severe renal impairment
  • Significant bleeding diathesis

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Otro: 6 participants with mild renal impairment
Renal Impairment Mild: creatinine clearance, 50 to 80 milliliters per minute (mL/min)
No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
Otro: 6 participants with moderate renal impairment
Renal Impairment Moderate: creatinine clearance, 30 to 49 mL/min
No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
Otro: 6 participants with severe renal impairment
Renal Impairment Severe: creatinine clearance, 15 to 29 mL/min
No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
Otro: 8 participants normal renal status
Renal status normal as defined by creatinine clearance ≥ 81 mL/min, otherwise age, gender, and smoking characteristics matching renal-impaired participants
No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
Otro: 6 participants with mild hepatic impairment
Hepatic impairment mild: total score on the Child-Pugh classification system between 5 and 6
No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
Otro: 6 participants with moderate hepatic impairment
Hepatic impairment moderate: total score on the Child-Pugh classification system between 7 and 9
No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
Otro: 6 participants with severe hepatic impairment
Hepatic impairment severe: total score on the Child-Pugh classification system between 10 and 15
No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
Otro: 8 participants normal hepatic status
Hepatic status normal, otherwise age, gender, and smoking characteristics matching hepatic-impaired participants
No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
Number of participants with any serious adverse event and any non-serious adverse event
Periodo de tiempo: 1 week
1 week

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

2 de diciembre de 2016

Finalización primaria (Actual)

8 de julio de 2017

Finalización del estudio (Actual)

8 de julio de 2017

Fechas de registro del estudio

Enviado por primera vez

16 de diciembre de 2016

Primero enviado que cumplió con los criterios de control de calidad

19 de diciembre de 2016

Publicado por primera vez (Estimar)

20 de diciembre de 2016

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

7 de septiembre de 2018

Última actualización enviada que cumplió con los criterios de control de calidad

6 de septiembre de 2018

Última verificación

1 de septiembre de 2018

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • E7080-A001-010

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

3
Suscribir